Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway

NCT00456898 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Major
Diabetic Neuropathies
Fibromyalgia
Vasomotor Symptoms

Interventions

DRUG: desvenlafaxine sustained release (DVS SR)
DRUG: Paroxetine
DRUG: Codeine

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer